Center for Devices and Radiological Health and

Al Qurayn, Egypt

Center for Devices and Radiological Health and

Al Qurayn, Egypt

Time filter

Source Type

PubMed | U.S. Food and Drug Administration, Divisions of Hematology and Immunology Devices and, Divisions of Hematology and Immunology Devices and. and Center for Devices and Radiological Health and
Type: Journal Article | Journal: Clinical chemistry | Year: 2015

Mass spectrometry-based in vitro diagnostic devices that measure proteins and peptides are underutilized in clinical practice, and none has been cleared or approved by the Food and Drug Administration (FDA) for marketing or for use in clinical trials. One way to increase their utilization is through enhanced interactions between the FDA and the clinical mass spectrometry community to improve the validation and regulatory review of these devices. As a reference point from which to develop these interactions, this article surveys the FDAs regulation of mass spectrometry-based devices, explains how the FDA uses guidance documents and standards in the review process, and describes the FDAs previous outreach to stakeholders. Here we also discuss how further communication and collaboration with the clinical mass spectrometry communities can identify opportunities for the FDA to provide help in the development of mass spectrometry-based devices and enhance their entry into the clinic.


PubMed | U.S. Food and Drug Administration and Center for Devices and Radiological Health and
Type: | Journal: Pharmaceutical development and technology | Year: 2016

Potential connections between release profiles and solvent evaporation rates alongside polymer chemistry were elucidated for the release of tetracycline hydrochloride from two different poly (d, l-lactide-co-glycolide) (PLGA) film matrices containing high drug fractions (50%, 30%, and 15%), and prepared at two distinct solvent evaporation rates. At highest tetracycline concentrations (50%), (i) the early release rates were 0.5g/min in all cases; (ii) release was linear from systems fabricated with lower lactic content and slower solvent evaporation rate and bimodal from systems fabricated with higher lactic content and faster evaporation rate; (iii) surface fractions covered by the drug were similar at both evaporation rates for 85:15 PLGA but very different for 50:50 PLGA, leading to unexpectedly reduced early release from 50:50 PLGA than from 85:15 PLGA when both the matrices were fabricated using a slower evaporation rate. These features remained unaffected in case of low drug concentration. Results suggested that during the formation of the drug-polymer microstructure, the combined effect of polymer chemistry and solvent evaporation rate sets apart the surface characteristics and the initial release profiles of systems containing high drug fraction, and an appropriate combination of these parameters may be utilized to control the early stage of drug release.

Loading Center for Devices and Radiological Health and collaborators
Loading Center for Devices and Radiological Health and collaborators